Oral medicine for angioedema attacks in children with HAE
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests an oral medication (sebetralstat) for treating angioedema attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal is to see if this medicine can safely relieve swelling and pain during an attack, offering a convenient at-home treatment option for kids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 11 years old.
- Your child must have a confirmed diagnosis of hereditary angioedema (HAE).
- Your child must weigh more than 9.5 kg (about 21 pounds).
- Your child must not have other forms of angioedema (like acquired angioedema or low C1-inhibitor not caused by HAE).
- Your child must not have severe liver disease.
- Your child must not be hypersensitive (allergic) to sebetralstat or its ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sebetralstat can prevent swelling attacks before medical procedures in people with HAE types I or II. You take the medicine short-term before your procedure to see if it helps protect you from an attack.
This study tests a new medicine called ADX-324 to see if it can prevent HAE attacks in adults with type I or II HAE. If you've had attacks recently and are willing to pause your current prevention medication, this trial may be an option.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This study lets people who were already taking berotralstat through earlier BioCryst studies keep the treatment going. It looks at safety and ongoing benefit for preventing hereditary angioedema attacks.
This expanded access program offers an investigational medication called deucrictibant immediate-release to people with hereditary angioedema (HAE) who have no good treatment options for their acute attacks. It aims to provide relief when other approved therapies haven't worked or aren't suitable.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
Hear when a new Hereditary Angioedema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.